PACIFIC-4 is an international, phase 3 study including a cohort of 60 EGFR-mutant NSCLC patients with localized disease who are candidates for SBRT followed by osimertinib 80 mg per os daily for up to 36 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.